secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001213900-23-084969
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics Q3 update: expands tecarfarin to LVAD/APS, cash $9.1M
---------------------------------------------------------------------------

- Expanded tecarfarin development beyond ESKD with AFib to include LVAD and APS, adding $1.5B annual U.S. market opportunity.
- Total addressable market for tecarfarin now over $2 billion annually in the U.S.
- Q3 2023 operating expenses (non-cash) totaled $989,000; cash used in operations $628,000.
- Cash balance as of Sept 30, 2023 was $9.1 million, providing flexibility to initiate pivotal trial in 2024.
- Completed $7.5 million private placement at $1.75/share in July 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390023084969/0001213900-23-084969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390023084969/ea187953-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-084969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer